BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19406048)

  • 21. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
    Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
    J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.
    Liu Y
    Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC).
    Fallanca F; Alongi P; Incerti E; Gianolli L; Picchio M; Kayani I; Bomanji J
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1837-48. PubMed ID: 27154522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.
    Khong PL; Huang B; Lee EY; Chan WK; Kwong YL
    J Nucl Med; 2014 Jun; 55(6):911-6. PubMed ID: 24819420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic value of CT, PET and combined PET/CT performed with low-dose unenhanced CT and full-dose enhanced CT in the initial staging of lymphoma.
    Pinilla I; Gómez-León N; Del Campo-Del Val L; Hernandez-Maraver D; Rodríguez-Vigil B; Jover-Díaz R; Coya J
    Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):567-75. PubMed ID: 21150860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overview of early response assessment in lymphoma with FDG-PET.
    MacManus MP; Seymour JF; Hicks RJ
    Cancer Imaging; 2007; 7(1):10-8. PubMed ID: 17766210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: Systematic review and meta-analysis.
    Adams HJA; Kwee TC
    Eur J Radiol; 2016 Nov; 85(11):1963-1970. PubMed ID: 27776647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M
    Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PET/CT: appropriate application in lymphoma.
    Wang X
    Chin Clin Oncol; 2015 Mar; 4(1):4. PubMed ID: 25841711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
    Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
    Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
    Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
    Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PET and PET/CT in management of the lymphomas.
    Podoloff DA; Macapinlac HA
    Radiol Clin North Am; 2007 Jul; 45(4):689-96, vii. PubMed ID: 17706533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The value of (18) F-fluorodeoxyglucose positron emission tomography for prediction of treatment response in gastrointestinal stromal tumors: a systematic review and meta-analysis.
    Hassanzadeh-Rad A; Yousefifard M; Katal S; Asady H; Fard-Esfahani A; Moghadas Jafari A; Hosseini M
    J Gastroenterol Hepatol; 2016 May; 31(5):929-35. PubMed ID: 26642423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
    Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G
    J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
    Bodet-Milin C; Kraeber-Bodéré F; Dupas B; Morschhauser F; Gastinne T; Le Gouill S; Campion L; Harousseau JL; Wegener WA; Goldenberg DM; Huglo D
    Haematologica; 2008 Mar; 93(3):390-7. PubMed ID: 18268287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
    Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
    Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 18F-FDG PET, combined FDG-PET/CT and MRI for evaluation of bone marrow infiltration in staging of lymphoma: a systematic review and meta-analysis.
    Wu LM; Chen FY; Jiang XX; Gu HY; Yin Y; Xu JR
    Eur J Radiol; 2012 Feb; 81(2):303-11. PubMed ID: 21145680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 18F-fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer: systematic review of the literature.
    Rebollo Aguirre AC; Ramos-Font C; Villegas Portero R; Cook GJ; Llamas Elvira JM; Tabares AR
    Ann Surg; 2009 Aug; 250(2):247-54. PubMed ID: 19638908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.